invasive aspergillosis in children in Saint-Petersburg

We observed 567 patients with invasive aspergillosis in 19 hospitals of St.-Petersburg from 1998 to 2012 years. It is known that invasive aspergillosis is a severe opportunistic infection with high mortality. The most severe invasive aspergillosis we observed in children. We analyzed the risk factors, etiology, basic clinical signs and treatment of invasive aspergillosis in children.

1. Внутрибольничные инфекции. Под ред. Р. П. Венцеля, 2‑е изд., перераб. и доп. М.: Медицина, 2004. 840 с.

2. Климко Н. Н. Инвазивный аспергиллез у гематологических и онкологических больных. Онкогематол 2006;1(1):14–21.

3. Климко Н. Н. Микозы: диагностика и лечение. М.: Ви Джи Групп, 2008. 336 с.

4. Козлов Р. С. Нозокомиальные инфекции: эпидемиология, патогенез, профилактика, контроль. Клин микробиол и антимикроб химиотер 2000;1(2):16–30.

5. Фокин А. А., Галкин Д. В., Мищенко В. М. и др. Уроки эпидемиологических исследований нозокомиальных инфекций в России. Клин микробиол и антимикроб химиотер 2008;10(1):4–14.

6. Хостелиди С. Н. Клинико-лабораторные особенности внутрибольничного инвазивного аспергиллеза. Автореф. дис. … канд. мед. наук. СПб., 2011. 22 с.

7. Baddley J. W., Andes D. R., K. A. Marr et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Сlin Infect Dis 2010;50:1559–67.

8. Beck-Sagué C., Jarvis W. R. National Nosocomial Infection Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in United states, 1980–1990. J Infect Dis 1993;167(5):1247–51.

9. Boon A. P., OʼBrien D., Adams D. H. 10‑year review of invasive aspergillosis detected at necropsy. J Clin Pathol 1991;44(6):452–4.

10. Burgos A., Zaoutis T. E., Dvorak C. C. et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 2008;5:1286–94.

11. Cornillet A., Camus C., Nimubona S. et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6‑year survey. Сlin Infect Dis 2006;43(5):577–84.

12. De Pauw B., Walsh T. J., Donnelly J. P. et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer / Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC / MSG) Consensus Group. Сlin Infect Dis 2008;46:1813–21.

13. Denning D. W. Aspergillosis. UK: United Kingdom Copyright, 2007. 76 p.

14. ESIL-3. 2009//hppt://www.eortc.be /cervices / unit / dg / documents / 06.Antifungaltherapy.pdf

15. Gerson S. L., Talbot G. H., Hurwitz S. et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann I Med 1984;100:345–51.

16. Greene R. E., Schlamm H. T., Oestmann J. W. et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Сlin Infect Dis 2007;44:373–9.

17. Groll A. H., Shah P. M., Mentzel C. et al. Trends in the postmortem epidemiology of fungal infections at a university hospital. J Infect Dis 2000;31:23–32.

18. Herbrecht R., Denning D. W., Patterson T. F. et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408–15.

19. Hoenigl M., Zollner-Schwetz I., Sill H. et al. Epidemiology of invasive fungal infections and rationale for antifungal therapy in patients with haematological malignancies. Mycoses 2011;54(5):454–9.

20. Hoffman H. L., Rathbun R. C. Review of the safety and efficacy of voriconazole. Exp Opin Invest Drugs 2002;11(3):409–29.

21. Horger M., Einsele H., Schumacher U. et al. Invasive pulmonary aspergillosis: frequency and meaning of the «hypodense sign» on unenhanced CT. Br Radiol 2005;78:697–703.

22. Lehrnbecher T., Groll A. H. Invasive fungal infections in the pediatric population. Expert Rev Anti Infect Ther 2011;9:275–8.

23. McNeil M.M., Nash S. L., Hajjeh R. A. et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Сlin Infect Dis 2001;33:641–7.

24. Meersseman W., Lagrou K., Maertens J. Galactomannan in bronchoalveolar lavage fluid a tool for diagnosing aspergillosis in intensive care unit patients. Аm J Respir Crit Care Med 2008;177:27–34.

25. Nivoix Y., Velten M., Letscher-Bru V. Factors associated with overall and attributable mortality in invasive aspergillosis. Сlin Infect Dis 2008;47(9):1176–84.

26. Pagano L., Caira M., Candoni A. et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006;47(8):1068–75.

27. Rotstein C., Cummings K. M., Tidings J. et al. An outbreak of invasive aspergillosis among allogeneic bone marrow transplants: a case-control study. Infect Control 1985;6(9):347–55.

28. Segal В. Н., Herbrecht R., Stevens D. A. Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. Сlin Infect Dis 2008;47:674–83.

29. Vonberg R. P., Gastmeier P. Nosocomial aspergillosis in outbreak settings. J Hosp Infect 2006;63(3):246–54.